anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The world-wide prevalence of myopia (nearsightedness) is increasing, but its pathogenesis is incompletely understood. Among many putative mechanisms, laboratory and clinical findings have implicated circadian biology in the etiology of myopia. Consistent with a circadian hypothesis, we recently reported a marked variability in diurnal patterns of gene expression in two crucial tissues controlling post-natal refractive development - the retina and choroid-at the onset of form-deprivation myopia in chick, a widely studied and validated model. To extend these observations, we assayed gene expression by RNA-Seq in retina and choroid during the progression of established unilateral form-deprivation myopia of chick. We assayed gene expression every 4 hours during a single day from myopic and contralateral control eyes. Retinal and choroidal gene expression in myopic vs. control eyes during myopia progression differed strikingly at discrete times during the day. Very few differentially expressed genes occurred at more than one time in either tissue during progressing myopia. Similarly, Gene Set Enrichment Analysis pathways varied markedly by time during the day. Some of the differentially expressed genes in progressing myopia coincided with candidate genes for human myopia, but only partially corresponded with genes previously identified at myopia onset. Considering other laboratory findings and human genetics and epidemiology, these results further link circadian biology to the pathogenesis of myopia; but they also point to important mechanistic differences between the onset of myopia and the progression of established myopia. Future laboratory and clinical investigations should systematically incorporate circadian mechanisms in studying the etiology of myopia and in seeking more effective treatments to normalize eye growth in children.
Adalimumab-aaty is intended for use under the guidance and supervision of a physician. A patient may self-inject Adalimumab-aaty or a caregiver may inject Adalimumab-aaty using either the Adalimumab-aaty AI or Adalimumab-aaty prefilled syringe if a physician determines that it is appropriate, and with medical follow-up, as necessary, after proper training in subcutaneous injection technique.

Adalimumab-aaty can be taken out of the refrigerator for about 15 to 30 minutes before injecting to allow the liquid to come to room temperature. Do not remove the cap or cover while allowing it to reach room temperature. Do not shake. Carefully inspect the solution in the Adalimumab-aaty AI or Adalimumab-aaty prefilled syringe for particulate matter and discoloration prior to subcutaneous administration. If particulates and discolorations are noted, do not use the product. Adalimumab-aaty does not contain preservatives; therefore, discard unused portions of drug remaining from the syringe.

Instruct patients using the Adalimumab-aaty AI or Adalimumab-aaty prefilled syringe to inject the full amount in the syringe, according to the directions provided in the Instructions for Use [see Instructions for Use].

Injections should occur at separate sites in the thigh or abdomen. Rotate injection sites and do not give injections into areas where the skin is tender, bruised, red or hard.

If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.
The invention discloses a radioisotope 18F substituted thiamine, a synthesis method thereof and application of the radioisotope 18F substituted thiamine to PET/CT of small animals. The radioisotope 18F substituted thiamine has the structural formula as shown in the specification. The synthesis method comprises the step of carrying out radiochemical synthesis by using the existing precursor. According to the invention, a PET imaging agent is prepared by substituting hydroxyl on a hydroxyethyl thiazole ring of thiamine with radioisotope 18F. The radioisotope 18F substituted thiamine can successfully enter different strains of rat brains, and the intake of thiamine-deficient rat brains is remarkably larger than a normal contrast. The radioisotope 18F substituted thiamine provides conditions for preparing a brain imaging agent and a tumor imaging agent for clinically treating senile dementia.
Serotonergic antidepressants, including REMERON/REMERONSolTab, can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. John's Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see Contraindications (4), Drug Interactions (7)] . Serotonin syndrome can also occur when these drugs are used alone. 

Serotonin syndrome signs and symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).

The concomitant use of REMERON/REMERONSolTab with MAOIs is contraindicated. In addition, do not initiate REMERON/REMERONSolTab in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection). If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking REMERON/REMERONSolTab, discontinue REMERON/REMERONSolTab before initiating treatment with the MAOI [see Contraindications (4), Drug Interactions (7)] . 

Monitor all patients taking REMERON/REMERONSolTab for the emergence of serotonin syndrome. Discontinue treatment with REMERON/REMERONSolTab and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of REMERON/REMERONSolTab with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.
As chronic inflammation and oxidative stress cause various diseases in the human body, this study aimed to develop functional materials to prevent inflammation and oxidative stress. This study investigated the biological function and components of Terminalia catappa L. extract prepared using its leaves and branches (TCE). TCE was determined using ultraperformance liquid chromatography-quadrupole-time-of-flight mass spectrometry. Using RAW 264.7 mouse macrophages, inhibitory effects of the identified compounds on nitric oxide (NO) and reactive oxygen species (ROS) generation were analyzed. Therefore, α-punicalagin was selected as an active compound with the highest content (986.6 ± 68.4 μg/g) and physiological activity. TCE exhibited an inhibitory effect on lipopolysaccharide (LPS)-induced inflammatory markers, including NO, inducible nitric oxide synthase, and inflammatory cytokines without exerting cytotoxicity. Moreover, TCE prevented excessive ROS production mediated by LPS and upregulated hemeoxygenase-1 expression via the nuclear translocation of nuclear factor erythroid 2-related factor 2. Interestingly, TCE prevented LPS-induced mitochondrial membrane potential loss, mitochondrial ROS production, and dynamin-related protein 1 phosphorylation (serine 616), a marker of abnormal mitochondrial fission. Furthermore, TCE considerably repressed the activation of LPS-induced mitogen-activated protein kinase pathway. Thus, TCE is a promising anti-inflammatory and antioxidant pharmaceutical or nutraceutical, as demonstrated via mitochondrial dysfunction and cellular signaling pathway regulation.
Using poly (vanillin-co-chitosan)/functionalized MWCNTs/GCE (PV-CS/f-MWCNTs/GCE) as a polymeric nanocomposite modified electrode, the present investigation has been conducted on the electrochemical detection of α-lipoic acid (α-LA) to prevent the activation of microglia inflammation of the nervous system. The manufacture of modified polymeric nanocomposite electrodes was carried out using the established electropolymerization process. Field emission scanning electron microscopy (FE-SEM) and X-ray diffraction (XRD) analyses of structure revealed that the electropolymerization of poly (vanillin-co-chitosan) on the surface of the f-MWCNTs modified electrode was successful. Vanillin-co-chitosan electropolymerization on f-MWCNTs as electroactive sheets can enhance the signal for α-LA electrochemical sensors, according to research on the electrochemical characteristics utilizing cyclic voltammetry (CV) and differential pulse voltammetry (DPV) methodologies. The PV-CS/f-MWCNTs/GCE demonstrated that it had a sensitivity of 0.04664 μA/μM, a detection limit of 0.012 μM, and an excellent response, linear range, and wide linear range to α-LA from 0 to 3000 μM. The results of the application of PV-CS/f-MWCNTs/GCE for determining the concentration of α-LA in a prepared real sample of human serum by DPV and human lipoic acid ELISA Kit analyses via standard addition method illustrated the substantial conformity between the findings of both assays. The results of the DPV analyses resulted in acceptable recovery values (97.60%-99.10%) and appropriate values of the Relative Standard Deviation (RSD) (3.58%-5.07%), which demonstrated the great applicability and accuracy of the results of PV-CS/f-MWCNTs/GCE for determining α-LA concentration in biological fluids and pharmaceutical specimens.
The experimental group will receive 30 minutes robotic training sessions, 3 times per week for a total of 30 sessions supervised by a research assistant. Immediately following this robot training, these subjects will receive schedule (1-hour sessions, 3 times/week, 30 total sessions) of conventional therapy from an occupational therapist.
The invention relates to poly(propylene imine) glycodendrimers, abbreviated as GD-PPI, wherein GD is a dendrimer coated with a sugar selected from a group comprising monosaccharides, disaccharides and trisaccharides, and PPI is a poly(propylene imine) dendrimer selected from a group of third, fourth and fifth generation dendrimers with a level of coating (surface modification) with a selected sugar within a range above 5 to about 100%, for therapeutic use in neoplastic diseases associated with chromosomal and/or genetic aberrations typical of chronic B cell lymphoproliferative diseases. The above group of compounds includes novel poly(propylene imine) glycodendrimers, abbreviated as GD-PPI, wherein GD is a dendrimer coated with lactose (disaccharide) or mannose (monosaccharide), and PPI is as defined above. In addition, the poly(propylene imine) glycodendrimers, abbreviated as GD-PPI, wherein GD is a dendrimer coated with maltotriose (trisaccharide) with a level of coating within the range above 5 to about 100%, except the values from 35% to 45% and from 80% to 95% which are being excluded, and PPI is as defined above, are novel. Selected compounds from the group of glycodendrimers defined above are intended for the therapeutic use in proliferative neoplastic blood diseases with an impaired apoptosis mechanism. The invention relates also to pharmaceutical compositions comprising the afore-mentioned compounds as therapeutically active substances. The aforementioned compounds are used for the manufacture of medicaments against the indicated medical conditions and in methods of treatment of those medical conditions.
The invention discloses an externally-applied medicament for treating traumatic injuries simply. The externally-applied medicament contains the whole plant of hemiboea subcapitata. The externally-applied medicament is prepared through the following steps of: cleaning and crushing the whole plant of hemiboea subcapitata, and adding 0.5-fold strong wine to soak for 1 hour. A use method of the externally-applied medicament comprises the following steps of: applying the soaked liquid medicine to a wounded part, slightly massaging the wounded part, directly applying medicine dregs to the wounded part of a serious patient, and changing dressings once every 8 hours. The externally-applied medicament is simple in components, easy and rapid to prepare, simple to use, and quick in curative effect. Through clinical tests for many years, the externally-applied medicament has accurate curative effect and high-speed analgesia, and the wounded part can restore completely without any sequel after the medicament is applied to the wounded part for 5 or 6 times.
Investigating how cells and organisms sense and respond to O2 levels is essential to our understanding of physiology and pathology. This field has advanced considerably since the discovery of the major transcription factor family, hypoxia-inducible factor (HIF), and the enzymes that control its levels: prolyl hydroxylases (PHDs). However, with its expansion, new complexities have emerged. Herein we highlight three main areas where, in our opinion, the research community could direct some of their attention. These include non-transcriptional roles of HIFs, specificity and O2 sensitivity of 2-oxoglutarate-dependent dioxygenases (2-OGDDs), and new tools and methods to detect O2 concentrations in cells and organs. A greater understanding of these areas would answer big questions and help drive our knowledge of cellular responses to hypoxia forward.
Gene therapy of SCO is based on the transplantation of genetically modified HSCs. Several LV approaches based on gene addition consist in transducing patient HSCs with a lentiviral vector expressing an anti-sickling β-like globin chain such as use of β ΑS3  HBB anti-sickling variants. Here, the inventors have improved the design of the LV-AS3 vector to treat SCO patients. These LVs allow the simultaneous expression of the potent anti-sickling β ΑS3  -globin and an artificial miR (amiR) silencing the β S -globin. The reduction of β S -globin levels will increase the incorporation of β ΑS3  -globin in Hb tetramers, which should increase the proportion of corrected RBCs in SCO patients. The inventors selected the best-performing miRs, and modified the therapeutic β ΑS3  -globin transgene by inserting silent mutations to avoid the recognition by the amiR and the silencing of the transgene.
PROBLEM TO BE SOLVED: To obtain a medicine for phrophylaxis and treating constipation which is conveniently usable without side effect by formulating an aqueous extract of the mold of ferns as an active ingredient. SOLUTION: This medicine contains an aqueous extract of the mold of ferns collected from ancient strata as an active ingredient. The property of this aqueous extract is as follows, pH: 3.5±0.5; density; 1.003g/cm<3> : boiling point: 103 deg.C; color tone: almost colorless transparent; taste: slightly sour: order: odorless: amino acid content: 2.25 or less μg/l (the value determined by an automatic amino acid analyzer); mineral content: 216.3ppm (the value determinated by atomic absorption spectrometry): bacteria number (the value measured by the official method): viable count 300 or less/g, Caliform bacilli negative; no acute toxicity; skin irritation: feeble. The appropriate vessel is aseptically filled with the extract as it is and, when necessary, various sweeteners and aromatics are added to it to prepare the medicine.  The dose is at least 50ml/day/person, preferably 100-150ml/day/person. This medicine is safely usable for a long period of time and less costy.
Family members with this condition will continue to receive the usual treatment provided by their referral care center. In addition, we will optimize the treatment, with 3 two-hour psychoeducation sessions in group format each week (ED and PD, explanatory theories, available treatments, comorbidity with PD).
COVID-19 is a novel respiratory disease caused by coronavirus (SARS-CoV-2) and results in significant morbidity and mortality. To date there is no approved medication for the treatment of patients with COVID-19. Remdesivir is a broad-spectrum antiviral nucleotide analogue that inhibits RNA-dependent RNA polymerase activity among a diverse group of RNA viruses. Non-clinical and clinical data suggest that Remdesivir may be useful for the treatment of COVID-19. WHO has identified Remdesivir as a candidate drug of interest to be studied in clinical trials. This retrospective study is designed to analyze the data collected during the routine care of patients who have benefited from this therapy.
BACKGROUND: Excessive attention to pain, or hypervigilance, is associated with negative outcomes in chronic pain conditions such as fibromyalgia. The Pain Vigilance and Awareness Questionnaire (PVAQ) is a self-report questionnaire to measure attention to pain. This study aimed to evaluate the psychometric properties of a Swedish version of the PVAQ.
METHODS: Psychometric evaluation on cross-sectional data derived from a clinical trial for fibromyalgia (N = 274). We evaluated item characteristics, factor structure in a confirmatory factor analytic framework, internal consistency, and construct validity in terms of correlations with other clinical variables.
RESULTS: Though confirmatory factor analysis did not result in a satisfactory solution for the full 16-item scale, acceptable two-factor solutions could be based on either nine or eight items (the PVAQ-9 and PVAQ-8). Internal consistency for both the PVAQ-9 and PVAQ-8 were good to excellent, and associations with pain catastrophizing, anxiety, depression, disability, and overall fibromyalgia impact were largely supportive of construct validity. An unexpected result was that, contrary to previous findings, no version of the PVAQ correlated consistently with pain intensity.
CONCLUSIONS: The Swedish PVAQ-9 and PVAQ-8 appear to have acceptable psychometric properties when administered online to individuals with fibromyalgia. The PVAQ-8 may be preferable due to being shorter and including an equal number of items per factor. Replication is warranted.
SIGNIFICANCE: This study evaluated the psychometric properties of a Swedish translation of the PVAQ in individuals with fibromyalgia. No convincing factor structure was found for the 16-item version. We could, however, confirm the factor structure of an established 9-item version (the PVAQ-9), and recommend further use of a new 8-item version (the PVAQ-8). In summary, the PVAQ exhibited more convincing psychometric properties when the number of items was roughly cut in half.
Streptococcus dysgalactiae subsp. equisimilis (SDSE) commonly causes a variety of infections in older individuals. However, respiratory infections are uncommon. We present the case of an older man with empyema due to SDSE subsequently to bacteraemia. He presented with a 1-day history of fever and laboratory findings revealed an increased white blood cell count and C- reactive protein (CRP) level. Chest CT revealed no infiltration and no pleural effusion. SDSE was detected in the blood cultures. Primary bacteraemia was suspected and antibiotic administration was initiated; however, 2 days later, his right breath sound diminished, and chest radiography revealed right pleural effusion. Thoracentesis yielded cloudy fluid with frank pus; thus, he was diagnosed with empyema due to SDSE, and a drainage tube was placed. Thereafter, his fever improved, and his CRP level decreased. Thus, SDSE can cause empyema probably by haemotological spread of SDSE to the pleura.
The invention discloses an atosiban Ban Zhi plastid gel composition. The composition comprises atosiban-loaded liposome, alcohols, disodium edetate, a water-soluble cooling agent, carbomers, triethanolamine and phytol. Wherein, the surface of the liposome loaded with atosiban is covalently bonded with a cell penetrating peptide. The existing atosiban injection is prepared into a liposome gel composition, and can be further prepared into a suppository, and the suppository is directly plugged into a vagina for use, so that the contraction of uterus is inhibited to avoid premature delivery. The cell penetrating peptide is an amphipathic polypeptide, can carry the drug into cells through endocytosis, and the histidine-glutamic acid copolymer on the polypeptide is a pH highly sensitive sequence, so that vaginal administration of the suppository type drug is facilitated. The liposome is used as a drug delivery carrier, so that the sudden release of the atosiban drug can be prevented, the release time of the drug can be controlled, and the sustained release effect is good.
This invention provides compositions and methods for the identification of lung cancer cells. In particular, polynucleotide sequences whose presence is indicative of lung cancer are disclosed. In addition, lung cancer can be identified by detecting the presence of the peptides encoded by these sequences. Antibodies to these peptides are also provided. Also included are gene delivery vehicles and host cells comprising these polynucleotides. Kits containing agents and instructions necessary to perform the screening and detecting methods are also provided.
This study was approved by the ethics committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. This randomized parallel group trial enrolled patients scheduled to receive thoracoscopic anatomic segmentectomy at Tongji Hospital. General anesthesia with double lumen endotracheal tube was administered to the patients. With the guidance of preoperative three-dimensional computed tomography bronchography and angiography, the targeted segment structures could be precisely dissected, and then intersegmental demarcation was confirmed by the modified inflation-deflation method in this study. In group A (100% oxygen), after dividing all the targeted vascular and bronchial structures, the lung of the operating side was re-inflated with 100% oxygen. In group B (Carbon dioxide), after the targeted segment structures were successfully dissected, the collapsed operative lung was completely re-expanded with carbon dioxide. The purpose of this study was to investigate the feasibility and safety of carbon dioxide on the appearance time of satisfactory and ideal planes during segmentectomy. The starting time point of the intersegmental plane was when the whole lungs had completely re-expanded. The end point was when the preserved segment was fully deflated, and a boundary had formed between the targeted segment and the reserved lung.
The present invention relates to a local anesthetic capable of sustained release, which comprises a charged drug and a counterion ionically bound thereto. In the local anesthetic capable of sustained release, a water-soluble charged drug forms an ionic bonding with a counterion. Thus, there is an effect of sustained release of the local anesthetic drug in the ionic bonding. In addition, the local anesthetic shows effective long-term sustained release behavior as compared to the short-term release behavior of a conventional drug. Thus, it is possible to deliver a drug effectively to a target site and to reduce drug treatment frequency. Therefore, it is possible to reduce the inconvenience of a patient, who, otherwise, should come to a hospital to treat lesions, and to reduce the cost requiring for medical treatment. Further, there is an effect of reducing pain caused by lesions causing pain for a long time and by lesions, such as chronic pain, having unknown origins and therapies.